当前位置: 首页 > 期刊 > 《中国医学创新》 > 2025年第17期
编号:2390321
卡瑞利珠单抗联合化疗对晚期非小细胞肺癌患者肿瘤标志物及生存情况的影响
http://www.100md.com 2025年8月14日 中国医学创新 2025年第17期
     Influence of Camrelizumab Combined with Chemotherapy on Tumor Markers and Survival Status in Patients with Advanced Non-small CellLung Cancer/WANGLei,YANG Qin,CHENG Xiaobo,YANG Li, LI Qian.//Medical Innovation of China,2025,22(17): 035-038

    [Abstract]Objective: To analyze the influence of Camrelizumab combined with chemotherapy on patients with advanced non-small cellung cancer (NSCLC).Method: The clinical data of 82 patients with advanced NSCLC admited to angyang People's Hospital fromFebruary 2O20 to February 2O23 were reviewed.They were divided into two groups according to diferent treatment methods, with 41 cases in each group. The control group received chemotherapy,while the observation group was treated with Camrelizumab inaddition to the control group. The therapeutic effects of the two groups were compared.Result: The total effective rate and survival rate of the observation group were both higher than those of the control group ( P lt;0.05).Moreover,after the treatment,the levels of various tumor markers and C8 + in the observation group were lower than those in the control group ......

您现在查看是摘要页,全文长 11353 字符